{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:08:13Z","timestamp":1700698093600},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,4,11]],"date-time":"2013-04-11T00:00:00Z","timestamp":1365638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Angiogenesis is an essential process for the expansion of multiple myeloma (MM), in which many angiogenic factors participate. Endoglin (CD105) is a transforming growth factor\u2010\u03b2 co\u2010receptor, being mainly expressed in angiogenic endothelial cells and has been used as a marker of tumor angiogenesis, having prognostic potential. The aim of the study was to evaluate serum levels of soluble CD105 (sCD105) in MM patients, both during diagnosis and after effective conventional chemotherapy, in the plateau phase, and to correlate them with the clinical stage of the disease, as well as with the known angiogenic factors vascular endothelial growth factor, angiogenin and interleukin\u201018 (IL\u201018). Serum levels of the aforementioned factors were measured, by enzyme\u2010linked immunosorbent assay, in 56 newly diagnosed MM patients, in 35 of them who entered plateau phase and in 24 healthy controls. Bone marrow aspirations were also performed in all patients to determine plasma cell infiltration. All measured cytokines were higher in MM patients compared with controls and with advancing disease stage (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 for all cases). Furthermore, the values of all factors decreased significantly in the plateau phase (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 for all cases). Serum levels of sCD105 correlated with the other angiogenic cytokines, whereas only serum levels of angiogenin had prognostic value for the survival. In conclusion, CD105 and the angiogenic cytokines vascular endothelial growth factor, angiogenin and IL\u201018, seem to have emerging roles both in angiogenesis and tumor growth in MM. Copyright \u00a9 2013 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.2044","type":"journal-article","created":{"date-parts":[[2013,4,11]],"date-time":"2013-04-11T07:31:01Z","timestamp":1365665461000},"page":"201-205","source":"Crossref","is-referenced-by-count":11,"title":["Emerging roles of endoglin\/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients"],"prefix":"10.1002","volume":"31","author":[{"given":"CA","family":"Pappa","sequence":"first","affiliation":[{"name":"Hematology Department Venizelion Hospital of Heraklion  Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MG","family":"Alexandrakis","sequence":"additional","affiliation":[{"name":"Hematology Department University Hospital of Heraklion  Greece"},{"name":"Hematology Laboratory University Hospital of Heraklion  Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Boula","sequence":"additional","affiliation":[{"name":"Hematology Department Venizelion Hospital of Heraklion  Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FE","family":"Psarakis","sequence":"additional","affiliation":[{"name":"Hematology Laboratory University Hospital of Heraklion  Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Kolovou","sequence":"additional","affiliation":[{"name":"Hematology Department General Hospital of Chania  Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Bantouna","sequence":"additional","affiliation":[{"name":"Hematology Laboratory University Hospital of Heraklion  Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Stavroulaki","sequence":"additional","affiliation":[{"name":"Hematology Department Venizelion Hospital of Heraklion  Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Tsirakis","sequence":"additional","affiliation":[{"name":"Hematology Department University Hospital of Heraklion  Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,4,11]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"237","article-title":"Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation","volume":"52","author":"Griffioen AW","year":"2000","journal-title":"Pharmacol Rev"},{"key":"e_1_2_8_3_1","first-page":"800","article-title":"Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression","volume":"85","author":"Kumar S","year":"2004","journal-title":"Blood"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.02-0634rev"},{"key":"e_1_2_8_5_1","first-page":"1623","article-title":"Up\u2010regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy","volume":"12","author":"Burrows FJ","year":"1995","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00012413"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1100\/tsw.2010.230"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2005.09.009"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.07.001"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-4466"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1095"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-2-18"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1429"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(20000320)89:2<122::AID-IJC4>3.0.CO;2-M"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.10200"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.260133"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08288.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.8.2630"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0602313"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0121"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(03)00261-3"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.127241"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22705"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1044-579X(02)00133-5"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161206777947461"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.20076"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0214327"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04478"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1271\/bbb.120178"},{"key":"e_1_2_8_30_1","first-page":"2651","article-title":"Prognostic significance of the angiogenic factors angiogenin, endoglin and endostatin in cervical cancer","volume":"31","author":"Landt S","year":"2011","journal-title":"Anticancer Res"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-011-9387-6"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200331"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.235"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2004.05.002"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00253.x"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602952"},{"key":"e_1_2_8_37_1","first-page":"487","article-title":"Combined perioperative plasma endoglin and VEGF\u2010A assessment in colorectal cancer patients","volume":"46","author":"Mysliwiec P","year":"2008","journal-title":"Folia Histochem Cytobiol"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-007-9528-z"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.2478\/v10042-009-0004-4"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2012.01.012"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2044","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T05:02:58Z","timestamp":1700629378000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,11]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1002\/hon.2044"],"URL":"https:\/\/doi.org\/10.1002\/hon.2044","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,11]]}}}